Myovant shows disappointing prostate cancer data on the way to the FDA, stock sinks

Myovant $MYOV has been prepping relugolix for advanced prostate cancer over the last several months, looking to improve upon the old standard in AbbVie’s Lupron. But new data out Tuesday will not help its cause.